ReviewBritish journal of pharmacology2015
Ketamine and phencyclidine: the good, the bad and the unexpected.
Review in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Features of biliary tract diseases in ketamine abusers: a systematic review of case reports.Journal of medical case reports · 2024Pooled it
- Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.International journal of molecular sciences · 2022Pooled it
- Structural basis of opioid receptor activation by PCP and ketamine.Nature structural & molecular biology · 2026Article
- Central toxic effects of an antitumoral bufadienolide: In silico targets and in vivo findings.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- From lobotomy to connectomics: a critical review of contemporary psychosurgery.Frontiers in psychiatry · 2026Review
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- DFT and QTAIM insights into CScientific reports · 2025Article
- Pharmaco-EEG-Based Classification of Psychotropic Activity of a Novel Chromone-Containing Allylmorpholine in Rats.Advanced pharmaceutical bulletin · 2025Article
- A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Current issues in molecular biology · 2025Article
- Causes and management of acute oncological pain: a narrative review.Anaesthesia · 2025Review
- Association of Hallucinogen Use With Psychosocial Outcomes: Secondary Analysis of the Spinal Cord Injury Model Systems Database.Topics in spinal cord injury rehabilitation · 2025Article
- NMDA receptor antagonist induced c-Fos expression in the medial entorhinal cortex during postnatal development.Frontiers in neural circuits · 2025Article
- The impact of ketamine on cognitive outcomes in geriatric anesthesia: a comprehensive review.Frontiers in psychiatry · 2025Review
- Psychotropic Drugs Reemerging as Headache Medicines.CNS drugs · 2024Article
- [Psychedelic and dissociative agents in psychiatry: challenges in the treatment].Der Nervenarzt · 2024Review
- Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Synthesis and Structure-Activity Relationships for Glutamate Transporter Allosteric Modulators.Journal of medicinal chemistry · 2024Article
- Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.Molecules (Basel, Switzerland) · 2024Review
- Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model.International journal of molecular sciences · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The history of ketamine and phencyclidine from their development as potential clinical anaesthetics through drugs of abuse and animal models of schizophrenia to potential rapidly acting antidepressants is reviewed. The discovery in 1983 of the NMDA receptor antagonist property of ketamine and phencyclidine was a key step to understanding their pharmacology, including their psychotomimetic effects in man. This review describes the historical context and the course of that discovery and its expansion into other hallucinatory drugs. The relevance of these findings to modern hypotheses of schizophrenia and the implications for drug discovery are reviewed. The findings of the rapidly acting antidepressant effects of ketamine in man are discussed in relation to other glutamatergic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.